Screener / SEC EDGAR /CIK 0001384101 /10-K filed Feb 26, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Labs

Veracyte, Inc. VCYT

Compare with peers Embed
Planned sales, announced before they happen

10 trading plans running, 29 Form 144 notices for $18.0M

10-Q, 10-K and Form 144
Plans running now 10 Phil Febbo, Jens Holstein, John Leite, Muna Bhanji, Karin Eastham, Robert Epstein, Annie McGuire, Rebecca Chambers, •Phil Febbo
Plans adopted 29 reported since May 5, 2023 Form 144 notices 29 $18.0M the sellers expected to sell

What VCYT's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.

Plans adopted or ended

Trading plans · XBRL, 10-Q and 10-K

From Aug 21, 2025 to Nov 26, 2027. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired. The ten newest plans are drawn; all are in the table.

InsiderWhatDateReported in
Phil Febbo
Chief Scientific Officer and Chief Medical Officer
Adopted 10b5-1 plan Aug 12, 2026 10-Q Nov 5, 2026
What the company wrote
Phil Febbo, Chief Scientific Officer and Chief Medical Officer, adopted a new trading plan on August 12, 2026 (with the first trade under the new plan scheduled for approximately November 30, 2026). The trading plan will be effective until November 26, 2027 to sell an aggregate of (i) 8,000 shares of our common stock, plus (ii) between 50% and 100% of the net shares resulting from the vesting of 87,844 restricted stock units during the plan period (net shares are net of tax withholding).
Jens Holstein
Director
Adopted 10b5-1 plan Jun 12, 2026 10-Q Jul 31, 2026
What the company wrote
Jens Holstein, Director, adopted a new trading plan on June 12, 2026 (with the first trade under the new plan scheduled for approximately September 11, 2026). The trading plan will be effective until June 7, 2027 to sell an aggregate of 20,000 shares of our common stock.
John Leite
Global Chief Commercial Officer
Adopted 10b5-1 plan Jun 9, 2026 10-Q Jul 31, 2026
What the company wrote
John Leite, Global Chief Commercial Officer, adopted a new trading plan on June 9, 2026 (with the first trade under the new plan scheduled for approximately September 8, 2026). The trading plan will be effective until August 13, 2027 to sell 100% of the net shares resulting from the vesting of 44,270 restricted stock units during the plan period (net shares are net of tax withholding).
Muna Bhanji
Director
Adopted 10b5-1 plan Jun 2, 2026 10-Q Jul 31, 2026
What the company wrote
Muna Bhanji, Director, adopted a new trading plan on June 2, 2026 (with the first trade under the new plan scheduled for approximately September 1, 2026). The trading plan will be effective until August 31, 2027 to sell an aggregate of 3,728 shares of our common stock.
Karin Eastham
Director
Adopted 10b5-1 plan May 28, 2026 10-Q Jul 31, 2026
What the company wrote
Karin Eastham, Director, adopted a new trading plan on May 28, 2026 (with the first trade under the new plan scheduled for approximately August 27, 2026). The trading plan will be effective until May 7, 2027 to sell an aggregate of 23,841 shares of our common stock.
Robert Epstein
director
Adopted 10b5-1 plan Dec 5, 2025 10-K Feb 26, 2026
What the company wrote
Robert Epstein, director, adopted a new trading plan on December 5, 2025 (with the first trade under the new plan scheduled for approximately March 6, 2026). The trading plan will be effective until March 5, 2027 to sell an aggregate of 10,000 shares of our common stock.
Marc Stapley
Chief Executive Officer
Adopted 10b5-1 plan Nov 24, 2025 10-K Feb 26, 2026
What the company wrote
Marc Stapley, Chief Executive Officer, adopted a new trading plan on November 24, 2025 (with the first trade under the new plan scheduled for approximately March 3, 2026). The trading plan will be effective until August 31, 2026 to sell an aggregate of (i) 138,051 shares of our common stock, plus (ii) 100% of the net shares resulting from the vesting of 69,476 restricted stock units during the plan period (net shares are net of tax withholding).
Karin Eastham
Director
Adopted 10b5-1 plan Sep 5, 2025 10-Q Nov 5, 2025
What the company wrote
Karin Eastham, Director, adopted a new trading plan on September 5, 2025 (with the first trade under the new plan scheduled for approximately December 5, 2025). The trading plan will be effective until November 20, 2026 to sell an aggregate of 29,533 shares of our common stock.
Annie McGuire
General Counsel and Chief People Officer
Adopted 10b5-1 plan Aug 29, 2025 10-Q Nov 5, 2025
What the company wrote
Annie McGuire, General Counsel and Chief People Officer, adopted a new trading plan on August 29, 2025 (with the first trade under the new plan scheduled for approximately November 28, 2025). The trading plan will be effective until December 18, 2026 to sell an aggregate of (i) 7,671 shares of our common stock, plus (ii) specified percentages ranging between 33% and 100% of the net shares resulting from the vesting of 179,803 restricted stock units during the plan period (net shares are net of tax withholding).
Jens Holstein
Director
Adopted 10b5-1 plan Aug 21, 2025 10-Q Nov 5, 2025
What the company wrote
Jens Holstein, Director, adopted a new trading plan on August 21, 2025 (with the first trade under the new plan scheduled for approximately November 20, 2025). The trading plan will be effective until August 21, 2026 to sell an aggregate of 10,000 shares of our common stock.
Rebecca Chambers
Chief Financial Officer
Adopted 10b5-1 plan Aug 21, 2025 10-Q Nov 5, 2025
What the company wrote
Rebecca Chambers, Chief Financial Officer, adopted a new trading plan on August 21, 2025 (with the first trade under the new plan scheduled for approximately November 20, 2025). The trading plan will be effective until December 11, 2026 to sell an aggregate of (i) 10,000 shares of our common stock, plus (ii) 100% of the net shares resulting from the vesting of 82,188 restricted stock units during the plan period (net shares are net of tax withholding).
•Phil Febbo
Chief Scientific Officer and Chief Medical Officer
Adopted 10b5-1 plan Aug 21, 2025 10-Q Nov 5, 2025
What the company wrote
Phil Febbo, Chief Scientific Officer and Chief Medical Officer, adopted a new trading plan on August 21, 2025 (with the first trade under the new plan scheduled for approximately February 28, 2026). The trading plan will be effective until November 27, 2026 to sell an aggregate of (i) 13,425 shares of our common stock, plus (ii) 100% of the net shares resulting from the vesting of 26,514 restricted stock units during the plan period (net shares are net of tax withholding).
John Leite
Global Chief Commercial Officer
Adopted 10b5-1 plan Jun 9, 2025 10-Q Aug 7, 2025
What the company wrote
John Leite, Global Chief Commercial Officer, adopted a new trading plan on June 9, 2025 (with the first trade under the new plan scheduled for approximately September 8, 2025). The trading plan will be effective until September 18, 2026 to sell an aggregate of (i) 9,077 shares of our common stock, plus (ii) 100% of the net shares resulting from the vesting of 42,137 additional common stock during the plan period (net shares are net of tax withholding).
Robert Epstein
director
Adopted 10b5-1 plan Mar 6, 2025 10-Q May 8, 2025
What the company wrote
Robert Epstein, director, adopted a new trading plan on March 6, 2025 (with the first trade under the new plan scheduled for approximately June 5, 2025). The trading plan will be effective until May 29, 2026 to sell an aggregate of 21,473 shares of our common stock.
Evan Jones
director
Adopted 10b5-1 plan Dec 9, 2024 10-K Feb 28, 2025
What the company wrote
Evan Jones, director, adopted a new trading plan on December 9, 2024 (with the first trade under the new plan scheduled for March 12, 2025). The trading plan will be effective until March 11, 2026 to sell an aggregate of 48,196 shares of our common stock.
John Leite
Chief Commercial Officer, CLIA
Adopted 10b5-1 plan Dec 6, 2024 10-K Feb 28, 2025
What the company wrote
John Leite, Chief Commercial Officer, CLIA, adopted a new trading plan on December 6, 2024 (with the first trade under the new plan scheduled for March 7, 2025). The trading plan will be effective until December 31, 2025 to sell 100% of the net shares resulting from the vesting of 20,770 shares of common stock during the plan period (net shares are net of tax withholding).
Muna Bhanji
director
Adopted 10b5-1 plan Nov 11, 2024 10-K Feb 28, 2025
What the company wrote
Muna Bhanji, director, adopted a new trading plan on November 11, 2024 (with the first trade under the new plan scheduled for approximately June 13, 2025). The trading plan will be effective until February 27, 2026 to sell an aggregate of 4,589 shares of our common stock.
Marc Stapley
Chief Executive Officer
Adopted 10b5-1 plan Sep 13, 2024 10-Q Nov 7, 2024
What the company wrote
Marc Stapley, Chief Executive Officer, adopted a new trading plan on September 13, 2024 (with the first trade under the new plan scheduled for December 13, 2024). The trading plan will be effective until December 11, 2025 to sell 100% of the net shares resulting from the vesting of 151,087 common stock during the plan period (net shares are net of tax withholding).
Annie McGuire
General Counsel and Chief People Officer
Adopted 10b5-1 plan Sep 4, 2024 10-Q Nov 7, 2024
What the company wrote
Annie McGuire, General Counsel and Chief People Officer, adopted a new trading plan on September 4, 2024 (with the first trade under the new plan scheduled for December 4, 2024). The trading plan will be effective until December 15, 2025 to sell an aggregate of (i) 14,970 shares of our common stock, plus (ii) 100% of the net shares resulting from the vesting of 31,175 additional common stock during the plan period (net shares are net of tax withholding).
Phillip Febbo
Chief Scientific Officer and Chief Medical Officer
Adopted 10b5-1 plan Sep 4, 2024 10-Q Nov 7, 2024
What the company wrote
Phillip Febbo, Chief Scientific Officer and Chief Medical Officer, adopted a new trading plan on September 4, 2024 (with the first trade under the new plan scheduled for December 4, 2024). The trading plan will be effective until November 21, 2025 to sell an aggregate of (i) 100% of the net shares resulting from the vesting of 38,230 common stock during the plan period, plus (ii) 10% of the net shares resulting from the vesting of 25,528 additional common stock during the plan period (net shares are net of tax withholding).
Karin Eastham
director
Adopted 10b5-1 plan Aug 20, 2024 10-Q Nov 7, 2024
What the company wrote
Karin Eastham, director, adopted a new trading plan on August 20, 2024 (with the first trade under the new plan scheduled for November 19, 2024). The trading plan will be effective until November 14, 2025 to sell an aggregate of 38,955 shares of our common stock.
Rebecca Chambers
Chief Financial Officer
Adopted 10b5-1 plan Aug 13, 2024 10-Q Nov 7, 2024
What the company wrote
Rebecca Chambers, Chief Financial Officer, adopted a new trading plan on August 13, 2024 (with the first trade under the new plan scheduled for November 12, 2024). The trading plan will be effective until November 21, 2025 to sell an aggregate of 29,802 shares of our common stock.
Robert Epstein
director
Adopted 10b5-1 plan Aug 9, 2024 10-Q Nov 7, 2024
What the company wrote
Robert Epstein, director, adopted a new trading plan on August 9, 2024 (with the first trade under the new plan scheduled for approximately November 11, 2024). The trading plan will be effective until January 11, 2025 to sell an aggregate of 15,000 shares of our common stock.
Jens Holstein
director
Adopted 10b5-1 plan Mar 11, 2024 10-Q May 8, 2024
What the company wrote
Jens Holstein, director, adopted a new trading plan on March 11, 2024 (with the first trade under the new plan scheduled for June 10, 2024). The trading plan will be effective until December 31, 2024 to sell an aggregate of 10,000 shares of our common stock.
Karin Eastham
director
Adopted 10b5-1 plan Mar 8, 2024 10-Q May 8, 2024
What the company wrote
Karin Eastham, director, adopted a new trading plan on March 8, 2024 (with the first trade under the new plan scheduled for June 7, 2024). The trading plan will be effective until March 7, 2025 to sell an aggregate of 13,870 shares of our common stock.
John Leite
Chief Commercial Officer
Adopted 10b5-1 plan Mar 1, 2024 10-Q May 8, 2024
What the company wrote
John Leite, Chief Commercial Officer, CLIA, adopted a new trading plan on March 1, 2024 (with the first trade under the new plan scheduled for June 4, 2024). The trading plan will be effective until February 27, 2025 to sell an aggregate of (i) 5,252 shares of our common stock, plus (ii) 100% of the net shares resulting from the vesting of 5,183 additional common stock during the plan period (net shares are net of tax withholding).
Evan Jones
director
Adopted 10b5-1 plan Feb 28, 2024 10-Q May 8, 2024
What the company wrote
jVen Capital LLC (Evan Jones, director, is the managing member of jVen Capital LLC) adopted a new trading plan on February 28, 2024 (with the first trade under the new plan scheduled for June 10, 2024). The trading plan will be effective until December 31, 2025 to sell an aggregate of 35,173 shares of our common stock.
Evan Jones
director
Adopted 10b5-1 plan Feb 28, 2024 10-Q May 8, 2024
What the company wrote
Evan Jones, director, adopted a new trading plan on February 28, 2024 (with the first trade under the new plan scheduled for June 10, 2024). The trading plan will be effective until December 31, 2025 to sell an aggregate of 24,731 shares of our common stock.
Muna Bhanji
director
Adopted 10b5-1 plan Feb 27, 2024 10-Q May 8, 2024
What the company wrote
Muna Bhanji, director, adopted a new trading plan on February 27, 2024 (with the first trade under the new plan scheduled for approximately May 10, 2024). The trading plan will be effective until February 28, 2025 to sell an aggregate of 5,409 shares of our common stock.
Show the other 21 plans

From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 5, 2023.

Notices of planned sales

Form 144 · Form 144 XML, SEC

What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).

FiledSellerSharesValue
Oct 27, 2026 KARIN EASTHAM
Director
14,850 $716K
Oct 27, 2026 JENS HOLSTEIN
Director
7,500 $375K
Sep 24, 2026 JENS HOLSTEIN
Director
7,500 $352K
Sep 21, 2026 JOHN LEITE
Officer
4,015 $160K
Sep 14, 2026 JENS HOLSTEIN
Director
5,000 $205K
Sep 4, 2026 ANN MCGUIRE
Officer
3,254 $145K
Sep 4, 2026 REBECCA CHAMBERS
Officer
3,652 $163K
Sep 4, 2026 PHILLIP FEBBO
Officer
13,110 $586K
Sep 1, 2026 MUNA BHANJI
Director
3,728 $161K
Jun 18, 2026 KARIN EASTHAM
Director
3,729 $191K
Jun 4, 2026 ANN MCGUIRE
Officer
3,176 $155K
Jun 4, 2026 John Leite
Officer
13,975 $680K
Jun 4, 2026 MARC STAPLEY
Director, Officer
138,051 $6.7M
Jun 4, 2026 REBECCA CHAMBERS
Officer
3,561 $173K
May 20, 2026 ROBERT EPSTEIN
Director
10,000 $417K
May 6, 2026 ANN MCGUIRE
Officer
10,204 $336K
Mar 4, 2026 ANN MCGUIRE
Officer
6,658 $234K
Mar 4, 2026 John Leite
Officer
5,260 $185K
Mar 4, 2026 REBECCA CHAMBERS
Officer
18,341 $643K
Mar 4, 2026 MARC STAPLEY
Director, Officer
45,523 $1.6M
Mar 2, 2026 PHILLIP FEBBO
Officer
13,425 $491K
Dec 16, 2025 ANN MCGUIRE
Officer
10,739 $467K
Dec 5, 2025 KARIN EASTHAM
Director
20,000 $948K
Dec 4, 2025 ANN MCGUIRE
Officer
1,422 $68K
Dec 4, 2025 REBECCA CHAMBERS
Officer
13,278 $634K
Dec 4, 2025 MARC STAPLEY
Director, Officer
7,668 $366K
Nov 25, 2025 Evan Jones
Director
5,000 $247K
Nov 25, 2025 John Leite
Officer
4,086 $191K
Nov 20, 2025 JENS HOLSTEIN
Director
10,000 $424K
Show the other 21 notices

From the Form 144 XML filed with the SEC, since Nov 20, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.

Sources

Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.

Also

Insider trades: the Form 4s for the sales these plans led to.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/VCYT/export.csv") into a cell.

Next:Owners
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.